Product Code: TMRGL85710
Melasma Drug Treatment Market - Scope of Report
TMR's report on the global melasma drug treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global melasma drug treatment market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global melasma drug treatment market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the melasma drug treatment market.
Market Snapshot |
Market Value in 2023 | US$ 2.6 Bn |
Market Value in 2031 | US$ 5.2 Bn |
CAGR | 8.3% |
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global melasma drug treatment market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global melasma drug treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global melasma drug treatment market.
The report delves into the competitive landscape of the global melasma drug treatment market. Key players operating in the global melasma drug treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global melasma drug treatment market profiled in this report.
Key Questions Answered in Global Melasma Drug Treatment Market Report:
- What is the sales/revenue generated by melasma drug treatment across all regions during the forecast period?
- What are the opportunities in the global melasma drug treatment market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which segment is expected to generate the highest revenue globally in 2031?
- Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?
Melasma Drug Treatment Market - Research Objectives and Research Approach
The comprehensive report on the global melasma drug treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global melasma drug treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global melasma drug treatment market.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Melasma Drug Treatment Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Segment Definition
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Melasma Drug Treatment Market Analysis and Forecast, 2017-2031
- 4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
- 5.1. Key Industry Events
- 5.2. Disease Epidemiology
- 5.3. Regulatory Scenario
- 5.4. Pipeline Analysis
- 5.5. Covid-19 Impact Analysis
6. Global Melasma Drug Treatment Market Analysis and Forecast, by Type of Melasma
- 6.1. Introduction & Definition
- 6.2. Key Findings / Developments
- 6.3. Market Value Forecast, by Type of Melasma, 2017-2031
- 6.3.1. Epidermal Melasma
- 6.3.2. Dermal Melasma
- 6.3.3. Mixed Melasma
- 6.4. Market Attractiveness Analysis, by Type of Melasma
7. Global Melasma Drug Treatment Market Analysis and Forecast, by Route of Administration
- 7.1. Introduction & Definition
- 7.2. Key Findings / Developments
- 7.3. Market Value Forecast, by Route of Administration, 2017-2031
- 7.3.1. Topical
- 7.3.2. Oral
- 7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Melasma Drug Treatment Market Analysis and Forecast, by Gender
- 8.1. Introduction & Definition
- 8.2. Key Findings / Developments
- 8.3. Market Value Forecast, by Gender, 2017-2031
- 8.4. Market Attractiveness Analysis, by Gender
9. Global Melasma Drug Treatment Market Analysis and Forecast, by Drug Agent
- 9.1. Introduction & Definition
- 9.2. Key Findings / Developments
- 9.3. Market Value Forecast, by Drug Agent, 2017-2031
- 9.3.1. Hydroquinone
- 9.3.2. Topical Retinoid
- 9.3.3. Topical Steroid
- 9.3.4. Triple Combination Cream
- 9.3.5. Others
- 9.4. Market Attractiveness Analysis, by Drug Agent
10. Global Melasma Drug Treatment Market Analysis and Forecast, by Distribution Channel
- 10.1. Introduction & Definition
- 10.2. Key Findings / Developments
- 10.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 10.3.1. Offline
- 10.3.2. Online
- 10.4. Market Attractiveness Analysis, by Distribution Channel
11. Global Melasma Drug Treatment Market Analysis and Forecast, by Region
- 11.1. Key Findings
- 11.2. Market Value Forecast, by Region
- 11.2.1. North America
- 11.2.2. Europe
- 11.2.3. Asia Pacific
- 11.2.4. Latin America
- 11.2.5. Middle East & Africa
- 11.3. Market Attractiveness Analysis, by Region
12. North America Melasma Drug Treatment Market Analysis and Forecast
- 12.1. Introduction
- 12.2. Market Value Forecast, by Type of Melasma, 2017-2031
- 12.2.1. Epidermal Melasma
- 12.2.2. Dermal Melasma
- 12.2.3. Mixed Melasma
- 12.3. Market Value Forecast, by Route of Administration, 2017-2031
- 12.3.1. Topical
- 12.3.2. Oral
- 12.4. Market Value Forecast, by Gender, 2017-2031
- 12.4.1. Men
- 12.4.2. Women
- 12.5. Market Value Forecast, by Drug Agent, 2017-2031
- 12.5.1. Hydroquinone
- 12.5.2. Topical Retinoid
- 12.5.3. Topical Steroid
- 12.5.4. Triple Combination Cream
- 12.5.5. Others
- 12.6. Market Value Forecast, by Distribution Channel, 2017-2031
- 12.6.1. Offline
- 12.6.2. Online
- 12.7. Market Value Forecast, by Country, 2017-2031
- 12.7.1. U.S.
- 12.7.2. Canada
- 12.8. Market Attractiveness Analysis
- 12.8.1. By Type of Melasma
- 12.8.2. By Route of Administration
- 12.8.3. By Gender
- 12.8.4. By Drug Agent
- 12.8.5. By Distribution Channel
- 12.8.6. By Country
13. Europe Melasma Drug Treatment Market Analysis and Forecast
- 13.1. Introduction
- 13.2. Market Value Forecast, by Type of Melasma, 2017-2031
- 13.2.1. Epidermal Melasma
- 13.2.2. Dermal Melasma
- 13.2.3. Mixed Melasma
- 13.3. Market Value Forecast, by Route of Administration, 2017-2031
- 13.3.1. Topical
- 13.3.2. Oral
- 13.4. Market Value Forecast, by Gender, 2017-2031
- 13.4.1. Men
- 13.4.2. Women
- 13.5. Market Value Forecast, by Drug Agent, 2017-2031
- 13.5.1. Hydroquinone
- 13.5.2. Topical Retinoid
- 13.5.3. Topical Steroid
- 13.5.4. Triple Combination Cream
- 13.5.5. Others
- 13.6. Market Value Forecast, by Distribution Channel, 2017-2031
- 13.6.1. Offline
- 13.6.2. Online
- 13.7. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.7.1. U.K.
- 13.7.2. Germany
- 13.7.3. France
- 13.7.4. Spain
- 13.7.5. Italy
- 13.7.6. Rest of Europe
- 13.8. Market Attractiveness Analysis
- 13.8.1. By Type of Melasma
- 13.8.2. By Route of Administration
- 13.8.3. By Gender
- 13.8.4. By Drug Agent
- 13.8.5. By Distribution Channel
- 13.8.6. By Country/Sub-region
14. Asia Pacific Melasma Drug Treatment Market Analysis and Forecast
- 14.1. Introduction
- 14.2. Market Value Forecast, by Type of Melasma, 2017-2031
- 14.2.1. Epidermal Melasma
- 14.2.2. Dermal Melasma
- 14.2.3. Mixed Melasma
- 14.3. Market Value Forecast, by Route of Administration, 2017-2031
- 14.3.1. Topical
- 14.3.2. Oral
- 14.4. Market Value Forecast, by Gender, 2017-2031
- 14.4.1. Men
- 14.4.2. Women
- 14.5. Market Value Forecast, by Drug Agent, 2017-2031
- 14.5.1. Hydroquinone
- 14.5.2. Topical Retinoid
- 14.5.3. Topical Steroid
- 14.5.4. Triple Combination Cream
- 14.5.5. Others
- 14.6. Market Value Forecast, by Distribution Channel, 2017-2031
- 14.6.1. Offline
- 14.6.2. Online
- 14.7. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.7.1. China
- 14.7.2. Japan
- 14.7.3. India
- 14.7.4. Australia & New Zealand
- 14.7.5. Rest of Asia Pacific
- 14.8. Market Attractiveness Analysis
- 14.8.1. By Type of Melasma
- 14.8.2. By Route of Administration
- 14.8.3. By Gender
- 14.8.4. By Drug Agent
- 14.8.5. By Distribution Channel
- 14.8.6. By Country/Sub-region
15. Latin America Melasma Drug Treatment Market Analysis and Forecast
- 15.1. Introduction
- 15.2. Market Value Forecast, by Type of Melasma, 2017-2031
- 15.2.1. Epidermal Melasma
- 15.2.2. Dermal Melasma
- 15.2.3. Mixed Melasma
- 15.3. Market Value Forecast, by Route of Administration, 2017-2031
- 15.3.1. Topical
- 15.3.2. Oral
- 15.4. Market Value Forecast, by Gender, 2017-2031
- 15.4.1. Men
- 15.4.2. Women
- 15.5. Market Value Forecast, by Drug Agent, 2017-2031
- 15.5.1. Hydroquinone
- 15.5.2. Topical Retinoid
- 15.5.3. Topical Steroid
- 15.5.4. Triple Combination Cream
- 15.5.5. Others
- 15.6. Market Value Forecast, by Distribution Channel, 2017-2031
- 15.6.1. Offline
- 15.6.2. Online
- 15.7. Market Value Forecast, by Country/Sub-region, 2017-2031
- 15.7.1. Brazil
- 15.7.2. Mexico
- 15.7.3. Rest of Latin America
- 15.8. Market Attractiveness Analysis
- 15.8.1. By Type of Melasma
- 15.8.2. By Route of Administration
- 15.8.3. By Gender
- 15.8.4. By Drug Agent
- 15.8.5. By Distribution Channel
- 15.8.6. By Country/Sub-region
16. Middle East & Africa Melasma Drug Treatment Market Analysis and Forecast
- 16.1. Introduction
- 16.2. Market Value Forecast, by Type of Melasma, 2017-2031
- 16.2.1. Epidermal Melasma
- 16.2.2. Dermal Melasma
- 16.2.3. Mixed Melasma
- 16.3. Market Value Forecast, by Route of Administration, 2017-2031
- 16.3.1. Topical
- 16.3.2. Oral
- 16.4. Market Value Forecast, by Gender, 2017-2031
- 16.4.1. Men
- 16.4.2. Women
- 16.5. Market Value Forecast, by Drug Agent, 2017-2031
- 16.5.1. Hydroquinone
- 16.5.2. Topical Retinoid
- 16.5.3. Topical Steroid
- 16.5.4. Triple Combination Cream
- 16.5.5. Others
- 16.6. Market Value Forecast, by Distribution Channel, 2017-2031
- 16.6.1. Offline
- 16.6.2. Online
- 16.7. Market Value Forecast, by Country/Sub-region, 2017-2031
- 16.7.1. GCC Countries
- 16.7.2. South Africa
- 16.7.3. Rest of Middle East & Africa
- 16.8. Market Attractiveness Analysis
- 16.8.1. By Type of Melasma
- 16.8.2. By Route of Administration
- 16.8.3. By Gender
- 16.8.4. By Drug Agent
- 16.8.5. By Distribution Channel
- 16.8.6. By Country/Sub-region
17. Competition Landscape
- 17.1. Market Player - Competition Matrix (by tier and size of companies)
- 17.2. Market Share Analysis, by Company (2022)
- 17.3. Company Profiles
- 17.3.1. AbbVie Inc.
- 17.3.1.1. Company Overview
- 17.3.1.2. Financial Overview
- 17.3.1.3. Product Portfolio
- 17.3.1.4. Business Strategies
- 17.3.1.5. Recent Developments
- 17.3.2. GALDERMA
- 17.3.2.1. Company Overview
- 17.3.2.2. Financial Overview
- 17.3.2.3. Product Portfolio
- 17.3.2.4. Business Strategies
- 17.3.2.5. Recent Developments
- 17.3.3. Obagi Cosmeceuticals LLC.
- 17.3.3.1. Company Overview
- 17.3.3.2. Financial Overview
- 17.3.3.3. Product Portfolio
- 17.3.3.4. Business Strategies
- 17.3.3.5. Recent Developments
- 17.3.4. Valeant Pharmaceuticals
- 17.3.4.1. Company Overview
- 17.3.4.2. Financial Overview
- 17.3.4.3. Product Portfolio
- 17.3.4.4. Business Strategies
- 17.3.4.5. Recent Developments
- 17.3.5. GLENMARK PHARMACEUTICALS LTD
- 17.3.5.1. Company Overview
- 17.3.5.2. Financial Overview
- 17.3.5.3. Product Portfolio
- 17.3.5.4. Business Strategies
- 17.3.5.5. Recent Developments
- 17.3.6. Abbott
- 17.3.6.1. Company Overview
- 17.3.6.2. Financial Overview
- 17.3.6.3. Product Portfolio
- 17.3.6.4. Business Strategies
- 17.3.6.5. Recent Developments
- 17.3.7. La Pristine
- 17.3.7.1. Company Overview
- 17.3.7.2. Financial Overview
- 17.3.7.3. Product Portfolio
- 17.3.7.4. Business Strategies
- 17.3.7.5. Recent Developments
- 17.3.8. MESOESTETIC
- 17.3.8.1. Company Overview
- 17.3.8.2. Financial Overview
- 17.3.8.3. Product Portfolio
- 17.3.8.4. Business Strategies
- 17.3.8.5. Recent Developments